🇨🇭 NOVN.SW — Novartis AG

Healthcare Mantener
← Volver

Precio actual

125,46 CHF

Máx. histórico

132,68

4 días

Split 40:1 del 07/05/2001

Caída desde máximo

-5,44%

Rango 52 semanas

96,03 – 132,68

Variación hoy

-3,18%

Cierre anterior

129,58

Rango de hoy

124,60 – 127,22

Volumen hoy

3.116.259

Información
Nombre completo
Novartis AG
Divisa
CHF
Mercado
Swiss
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
75.267
PER ⓘ
23,32 (puede no estar actualizado)
Dividend yield
2,86% (puede no estar actualizado)
Precio objetivo analistas
125,45 CHF (puede no estar actualizado)
Primera cotización
03/04/1995
Precio actualizado
hace 13 horas
Sobre la empresa

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Dividendos repartidos Total últimos 12 meses: 3,7000 CHF · Yield: 2,95%
Fecha de pago Importe por participación
24/02/2011 2,2000 CHF
02/03/2010 2,1000 CHF
27/02/2009 2,0000 CHF
29/02/2008 1,6000 CHF
09/03/2007 1,3500 CHF
03/03/2006 1,1500 CHF
04/03/2005 1,0500 CHF
27/02/2004 1,0000 CHF
07/03/2003 0,9500 CHF
26/03/2002 0,9000 CHF
27/03/2001 0,8500 CHF
17/04/2000 0,8000 CHF
26/04/1999 0,7250 CHF
24/04/1998 0,6250 CHF
25/04/1997 0,5000 CHF
Splits Registrados en el histórico de precios
Fecha Ratio
07/05/2001 40:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/09/2010 45,20 45,49 44,91 45,28 +0,65% 1,30% 6.681.989
02/09/2010 45,20 45,24 44,82 44,99 -0,65% 0,93% 6.148.449
01/09/2010 44,99 45,41 44,74 45,28 +1,31% 1,49% 6.802.201
31/08/2010 44,49 45,03 44,41 44,70 -0,65% 1,41% 7.116.411
30/08/2010 45,03 45,37 44,95 44,99 +0,75% 0,93% 4.952.212
27/08/2010 44,07 44,87 43,90 44,66 +1,91% 2,18% 6.527.196
26/08/2010 43,82 44,03 43,53 43,82 +0,48% 1,15% 4.604.385
25/08/2010 43,27 43,82 43,23 43,61 +0,87% 1,36% 6.308.786
24/08/2010 43,61 43,74 43,06 43,23 -1,25% 1,54% 4.984.342
23/08/2010 43,99 44,24 43,61 43,78 -0,19% 1,43% 3.857.748
20/08/2010 44,24 44,28 43,65 43,86 -0,57% 1,42% 6.113.689
19/08/2010 44,82 44,95 44,07 44,11 -1,40% 1,96% 4.359.983
18/08/2010 44,24 44,87 44,24 44,74 +0,66% 1,42% 4.839.374
17/08/2010 44,24 44,49 44,11 44,45 +0,76% 0,85% 3.775.326
16/08/2010 44,36 44,49 43,90 44,11 -0,66% 1,32% 3.397.290
13/08/2010 44,41 44,53 43,94 44,41 +0,47% 1,32% 4.481.448
12/08/2010 44,15 44,45 44,15 44,20 -0,56% 0,66% 4.419.004
11/08/2010 44,78 44,99 44,36 44,45 -1,49% 1,40% 6.329.399
10/08/2010 44,24 45,20 44,24 45,12 +2,08% 2,18% 7.349.816
09/08/2010 43,74 44,24 43,61 44,20 +1,93% 1,44% 3.930.180
06/08/2010 43,82 44,03 43,19 43,36 -1,24% 1,91% 4.460.048
05/08/2010 43,78 44,11 43,74 43,90 +0,58% 0,86% 4.241.404
04/08/2010 43,48 43,65 43,27 43,65 +0,10% 0,87% 4.252.174
03/08/2010 43,65 43,74 43,32 43,61 +0,48% 0,96% 5.205.487
02/08/2010 42,73 43,53 42,56 43,40 +2,47% 2,26% 5.150.407
30/07/2010 42,77 42,77 42,14 42,35 -0,88% 1,47% 5.989.977
29/07/2010 43,19 43,36 42,73 42,73 -0,87% 1,45% 4.385.636
28/07/2010 43,32 43,57 42,98 43,11 +0,10% 1,36% 5.305.216
27/07/2010 43,32 43,36 42,81 43,06 -0,19% 1,26% 6.718.975
26/07/2010 43,57 43,57 42,48 43,15 -0,58% 2,50% 8.753.012